Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Sep 28;4(1):16.
doi: 10.1186/1471-2261-4-16.

Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment

Ulrika Liljedahl  1 , Lars Lind, Lisa Kurland, Lars Berglund, Thomas Kahan, Ann-Christine Syvänen
Affiliations

Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment

Ulrika Liljedahl et al. BMC Cardiovasc Disord. .

Abstract

Background: Dyslipidemia has been associated with hypertension. The present study explored if polymorphisms in genes encoding proteins in lipid metabolism could be used as predictors for the individual response to antihypertensive treatment.

Methods: Ten single nucleotide polymorphisms (SNP) in genes related to lipid metabolism were analysed by a microarray based minisequencing system in DNA samples from ninety-seven hypertensive subjects randomised to treatment with either 150 mg of the angiotensin II type 1 receptor blocker irbesartan or 50 mg of the beta1-adrenergic receptor blocker atenolol for twelve weeks.

Results: The reduction in blood pressure was similar in both treatment groups. The SNP C711T in the apolipoprotein B gene was associated with the blood pressure response to irbesartan with an average reduction of 19 mmHg in the individuals carrying the C-allele, but not to atenolol. The C16730T polymorphism in the low density lipoprotein receptor gene predicted the change in systolic blood pressure in the atenolol group with an average reduction of 14 mmHg in the individuals carrying the C-allele.

Conclusions: Polymorphisms in genes encoding proteins in the lipid metabolism are associated with the response to antihypertensive treatment in a drug specific pattern. These results highlight the potential use of pharmacogenetics as a guide for individualised antihypertensive treatment, and also the role of lipids in blood pressure control.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of SNP genotype on the change in blood pressure after 12 weeks of treatment for the ten SNPs. For each of the SNPs, the pattern of change in blood pressure related to genotype is illustrated for the systolic blood pressure (SBP) and diastolic blood pressure (DBP) in separate panels. In each panel, the mean change in blood pressure is shown for the SNP genotypes in the atenolol treatment group on the left, and the corresponding results in the irbesartan treatment group are given on the right. The error bars corresponds to the standard error of the mean. The p-values indicating significance for the APOA-IV A1449G, APOA-V C31455T, APOB C711T and LDLR C16730T SNPs are given in the corresponding panels. The number of individuals of each genotype is shown above the bars in each panel.
See this image and copyright information in PMC

References

    1. Cadman PE, O'Connor DT. Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertens. 2003;12:61–70. doi: 10.1097/00041552-200301000-00011. - DOI - PubMed
    1. Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens. 2001;19:1–11. doi: 10.1097/00004872-200101000-00001. - DOI - PubMed
    1. Turner ST, Boerwinkle E. Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics. 2003;4:53–65. doi: 10.1517/phgs.4.1.53.22587. - DOI - PubMed
    1. Laragh JH, Lamport B, Sealey J, Alderman MH. Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension. 1988;12:223–226. - PubMed
    1. Lind L, Berne C, Andersson PE, Hanni A, Lithell H. Is insulin resistance a predictor of the blood pressure response to anti-hypertensive treatment? J Hum Hypertens. 1995;9:759–763. - PubMed

Publication types